Полиморфизм HLA-DRB1 и риск рассеянного склероза в детском возрасте и у взрослых: исследование случай–контроль

Связь предрасположенности к рассеянному склерозу (РС) с полиморфизмами гена HLA-DRB1 является наиболее сильной. Неясно, различаются ли аллели DRB1, ассоциированные с риском этого заболевания в популяциях взрослых и детей, проживающих в одинаковых экологических условиях.

Цель: сравнительная оценка ассоциаций полиморфизма гена HLA-DRB1 с риском РС с дебютом в детском возрасте и у взрослых в Алтайском крае.

Материал и методы. В исследовании случай–контроль приняли участие больные ремиттирующим РС, европеоиды, родившиеся и проживающие в Алтайском крае: 200 пациентов с дебютом РС во взрослом возрасте, 86 пациентов с дебютом РС в возрасте до 18 лет. Группа контроля — 200 добровольцев. Генотипирование проводили методом TaqMan-зондов.

Результаты. У европеоидов в Алтайскoм кpае генетическими фактopами pиска РС в детском возрасте, так же как у взрослых, являются аллели 03, 13, 15 гена HLA-DRB1. Протектерное влияние в отношении РС в детском возрасте могут оказывать аллели 01 и 07, у взрослых — аллели 01, 07, 11 и 16 гена HLA-DRB1.

Заключение. Можно полагать, что различие возраста дебюта РС не связано с различием аллелей риска этого заболевания гена HLA-DRB1 в возрастных группах до и после 18 лет.

1. Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз. М.: МЕДпресс-информ; 2016.

2. Alroughani R., Boyko A. Pediatric multiple sclerosis: a review. BMC neurology. 2018;18(1):27. https://doi.org/10.1186/s12883-018-1026-3

3. Tyshkov C.D., Charvet L.E., Krupp L.B. Multiple Sclerosis in Children. In: Rizvi S., Cahill J., Coyle P. (eds). Clinical Neuroimmunology. Current Clinical Neurology. Humana, Cham. 2020:179–197. https://doi.org/10.1007/978-3-030-24436-1_9

4. Alroughani R., Akhtar S., Ahmed S.F., Behbehani R., Al-Abkal J., Al-Hashel J. Incidence and prevalence of pediatric onset multiple sclerosis in Kuwait: 1994–2013. Journal of the neurological sciences. 2015;353(1–2):107–110. https://doi.org/10.1016/j.jns.2015.04.025

5. Бойко А.Н., Быкова О.В., Сиверцева С.А. Рассеянный склероз у детей и подростков: клиника, диагностика, лечение. М.: МИА; 2016:448 с.

6. Yan K., Balijepalli C., Desai K., Gullapalli L., Druyts E. Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. Multiple sclerosis and related disorders. 2020;44:102260. https://doi.org/10.1016/j.msard.2020.102260

7. Jeong A., Oleske D.M., Holman J. Epidemiology of PediatricOnset Multiple Sclerosis: A Systematic Review of the Literature. Journal of child neurology. 2019;34(12):705–712. https://doi.org/10.1177/0883073819845827

8. von Wyl V., Décard B.F., Benkert P., Lorscheider J., Hänni P., Lienert C. et al. Infl uence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. Eur J Neurol. 2020;27(6):1066–1075. https://doi.org/10.1111/ene.14191

9. Padilha I.G., Fonseca A.P.A., Pettengill A.L.M., Fragoso D.C., Pacheco F.T., Nunes R.H. et al. Pediatric multiple sclerosis: from clinical basis to imaging spectrum and diff erential diagnosis. Pediatric radiology. 2020;50(6):776–792. https://doi.org/10.1007/s00247-019-04582-3

10. Bar-Or A., Hintzen R.Q., Dale R.C., Rostasy K., Brück W., Chitnis T. Immunopathophysiology of pediatric CNS infl ammatory demyelinating diseases. Neurology. 2016;87(9):12–19. https://doi.org/10.1212/WNL.0000000000002821

11. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188. https://doi.org/10.1126/science.aav7188

12. Schmidt H., Williamson D., Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. American Journal of Epidemiology. 2007;165(10):1097–1109. https://doi.org/10.1093/aje/kwk118

13. Ramagopalan S.V., Morris A.P., Dyment D.A., Herrera B.M., DeLuca G.C., Lincoln M.R. et al. The inheritance of resistance alleles in multiple sclerosis. PLoS genetics. 2007;3(9):1607–1613. https://doi.org/10.1371/journal.pgen.0030150

14. Zhang Q., Lin C.Y., Dong Q., Wang J., Wang W. Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of nonfamily-based studies. Autoimmunity reviews. 2011;10(8):474–481. https://doi.org/10.1016/j.autrev.2011.03.003

15. Boiko A.N., Gusev E.I., Sudomoina M.A., Alekseenkov A.D., Kulakova O.G., Bikova O.V. et al. Association and linkage of juvenile MS with HLA-DR2(15) Neurology. 2002;58(4):658–660. https://doi.org/10.1212/wnl.58.4.658

16. Disanto G., Magalhaes S., Handel A.E., Morrison K.M., Sadovnick A.D., Ebers G.C. et al. Canadian Pediatric Demyelinating Disease Network. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology. 2011;76:781–786. https://doi.org/10.1212/WNL.0b013e31820ee1cd

17. Ramagopalan S.V., Knight J.C., Ebers G.C. Multiple sclerosis and the major histocompatibility complex. Current opinion in neurology. 2009;22(3):219–225. https://doi.org/10.1097/WCO.0b013e32832b5417

18. Rensel M. Long-Term Treatment Strategies of Pediatric Multiple Sclerosis, Including the use of Disease Modifying Therapies. Children (Basel). 2019;6(6):73. https://doi.org/10.3390/children6060073

19. Simone M., Chitnis T. Use of Disease-Modifying Therapies in Pediatric MS. Current treatment options in neurology. 2016;18(8):36. https://doi.org/10.1007/s11940-016-0420-7

20. Chitnis T., Pohl D. Pediatric demyelinating disorders Global updates, controversies, and future directions. Neurology. 2016;87(9):S1–S3. https://doi.org/10.1212/WNL.0000000000002882

21. Смагина И.В., Ельчанинова С.А., Золовкина А.Г., Игнатова Ю.Н., Кудрявцева Е.А. Генетические факторы риска рассеянного склероза в популяции Алтайского края. Журнал неврологии и психиатрии им. C.C. Корсакова. 2011;111(5):42– 45.

22. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M. et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of neurology. 2011;69(2):292–302. https://doi.org/10.1002/ana.22366

23. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. https://doi.org/10.1212/wnl.33.11.1444

24. Riccio M.E., Buhler S., Nunes J.M., Vangenot C., Cuénod M., Currat M. et al. 6(th) IHIW: analysis of HLA population data, with updated results for 1996 to 2012 workshop data (AHPD project report). International journal of immunogenetics. 2013;40(1):21–30. https://doi.org/10.1111/iji.12033

25. Terasaki P.I., Gjertson D.W., eds. HLA 1997. UCLA Tissue Typing Laboratory. Los Angeles: California; 1997:475 p.

26. Banwell B., Bar-Or A., Arnold D.L., Sadovnick D., Narayanan S., McGowan M. et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. The Lancet. Neurology. 2011;10(5):436–445. https://doi.org/10.1016/S1474-4422(11)70045-X

27. Gianfrancesco M.A., Stridh P., Rhead B., Shao X., Xu E., Graves J.S. et al. Network of Pediatric Multiple Sclerosis Centers (2017). Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017;88(17):1623–1629. https://doi.org/10.1212/WNL.0000000000003849

28. Anagnostouli M.C., Manouseli A., Artemiadis A.K., Katsavos S. HLA–DRB1* allele frequencies in pediatric, adolescent, and adult–onset multiple sclerosis patients, in a hellenic sample. Evidence for new and established associations. Journal of multiple sclerosis. 2014;1:104. http://dx.doi.org/10.4172/jmso.1000104

29. An Pelt E.D., Mescheriakova J.Y., Makhani N., Ketelslegers I.A., Neuteboom R.F., Kundu S. et al. Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology. 2013;81(23):1996–2001. https://doi.org/10.1212/01.wnl.0000436934.40034eb

30. Waubant E., Ponsonby A.L., Pugliatti M., Hanwell H., Mowry E.M., Hintzen R.Q. Environmental and genetic factors in pediatric infl ammatory demyelinating diseases. Neurology. 2016;87(9Suppl2):S20–S27. https://doi.org/10.1212/WNL.0000000000003029

31. Consortium TIMSGCtWTCC, Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cellmediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214–219. https://doi.org/10.1038/nature10251

32. Hollenbach J.A., Oksenberg J.R. The immunogenetics of multiple sclerosis: A comprehensive review. Journal of autoimmunity. 2015;64:13–25. https://doi.org/10.1016/j.jaut.2015.06.010

33. Kwon O.J., Karni A., Israel S., Brautbar C., Amar A., Meiner Z. et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. Archives of neurology. 1999;56(5):555–560. https://doi.org/10.1001/archneur.56.5.555

34. Cocco E., Sardu C., Pieroni E., Valentini M., Murru R., Costa G. et al. HLA-DRB1-DQB1 haplotypes confer susceptibility and resistance to multiple sclerosis in Sardinia. PloS one. 2012;7(4): e33972. https://doi.org/10.1371/journal.pone.0033972

35. Amirzargar A., Mytilineos J., Yousefi pour A., Farjadian S., Scherer S., Opelz G. et al. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients. European journal of immunogenetics. 1998;25(4):297–301. https://doi.org/10.1046/j.13652370.1998.00101.x

36. Brum D.G., Barreira A.A., Louzada-Junior P., MendesJunior C.T., Donadi E.A. Association of the HLA-DRB1*15 allele group and the DRB1*1501 and DRB1*1503 alleles with multiple sclerosis in White and Mulatto samples from Brazil. Journal of neuroimmunology. 2007;189(1–2):118–124. https://doi.org/10.1016/j.jneuroim.2007.06.009

37. Quelvennec E., Bera O., Cabre P., Alizadeh M., Smadja D., Jugde F. et al. Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specifi c and direct role of the HLA-DR locus in the syndrome. Tissue antigens. 2003;61(2):166–171. https://doi.org/10.1046/j.0001-2815.2002.00008.x

38. Ballerini C., Guerini F.R., Rombolà G., Rosati E., Massacesi L., Ferrante P. et al. HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. Journal of neuroimmunology. 2004;150(1–2):178–185. https://doi.org/10.1016/j.jneuroim.2004.01.015

39. Fernández O., Fernández V., Alonso A., Caballero A., Luque G., Bravo M. et al. DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. Journal of neurology. 2004;251(4):440–444. https://doi.org/10.1007/s00415-004-0350-2

40. Hillert J., Käll T., Olerup O., Söderström M. Distribution of HLADw2 in optic neuritis and multiple sclerosis indicates heterogeneity. Acta neurologica Scandinavica. 1996;94(3):161–166. https://doi.org/10.1111/j.1600-0404.1996.tb07047.x

41. Hensiek A.E., Sawcer S.J., Feakes R., Deans J., Mander A., Akesson E. et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72(2):184–187. http://dx.doi.org/10.1136/jnnp.72.2.184

42. Fukazawa T., Yamasaki K., Ito H., Kikuchi S., Minohara M., Horiuchi I. et al. Both the HLA-CPB1 and -DRB1 alleles correlate with risk for multiple sclerosis in Japanese: clinical phenotypes and gender as important factors. Tissue Antigens. 2000;55(3):199–205. https://doi.org/10.1034/j.1399-0039.2000.550302.x

43. McDonnell G.V., Mawhinney H., Graham C.A., Hawkins S.A., Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its infl uence on prognosis. J Neurol Sci. 1999;165(1):77–83. https://doi.org/10.1016/S0022-510X(99)00084-2

44. Modin H., Olsson W., Hillert J., Masterman T. Modes of action of HLA-DR susceptibility specifi cities in multiple sclerosis. American journal of human genetics. 2004;74(6):1321–1322. https://doi.org/10.1086/420977

45. Marrosu M.G., Murru M.R., Costa G., Cucca F., Sotgiu S., Rosati G. et al. Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. American journal of human genetics. 1997;61(2):454–457. https://doi.org/10.1016/S0002-9297(07)64074-9

46. Кaimen-Maciel D.R., Reiche E.M., Borelli S.D., Morimoto H.K., Melo F.C., Lopes J. et al. HLA-DRB1* allele-associated genetic susceptibility and protection against multiple sclerosis in Brazilian patients. Molecular medicine reports. 2009;2(6):993–998. https://doi.org/10.3892/mmr_00000204

47. Ramagopalan S.V., Morris A.P., Dyment D.A., Herrera B.M., DeLuca G.C., Lincoln M.R. et al. The inheritance of resistance alleles in multiple sclerosis. PLoS genetics. 2007;3(9):1607–1613. https://doi.org/10.1371/journal.pgen.0030150